Hikma Slashes Generics Forecast After Key Product Delay
Expected US Launch Of Authorized Generic Xyrem Slips To As Late As 2023
Just days after forecasting healthy generics sales growth for 2022, Hikma has significantly reduced its expectations for the year on news of a delay to its US launch of an authorized generic of Xyrem (sodium oxybate).
You may also be interested in...
As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.
The biggest loss of exclusivity in pharmaceutical history is set to steal headlines in the first month of 2023, as Teva begins a new year with a new CEO.
Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.